Science Corporation implants its vision-restoring chip in its first Stargardt disease patient

Science Corporation has placed its PRIMA vision chip in its first person with Stargardt disease, marking an early clinical milestone for a company whose ambitions extend beyond the eye. Chief executive Max Hodak disclosed the implantation during an appearance at TechCrunch Disrupt, presenting the procedure as part of a longer effort to develop new forms of brain-computer interface technology. The announcement establishes that the device has moved into use with a Stargardt patient; it does not, by itself, establish the degree of visual improvement achieved.

Stargardt disease is an inherited eye disorder associated with a progressive loss of central sight. That makes the first implantation significant both for the patient population targeted by the program and for Science Corporation's attempt to show that its neural-engineering approach can be used in a clinical setting. Central vision supports tasks such as reading and recognizing fine detail, so a therapy aimed at this part of sight faces a demanding standard. No patient-specific outcomes or timeline for those outcomes were disclosed in the announcement.

Hodak's framing put the retina at the center of the company's wider technical thesis. He described the retina as tissue within the central nervous system and argued that devices such as cochlear implants, retinal prostheses and motor prostheses can all be understood as varieties of brain-computer interfaces. That definition is broader than the popular image of a BCI as an electrode array placed directly in the brain. In this view, an implanted system that links nervous tissue to electronics can be a step toward the same broad goal.

PRIMA therefore occupies a strategic role beyond a single vision program. Science Corporation is using a retinal device to work on methods that could inform other neural technologies, while giving its initial clinical work a clear medical purpose. The company has said its near-term focus is on restoring vision for people with visual impairment. Hodak said this path also offers a way to test its methods and build a durable business before pursuing more expansive neural-engineering goals.

The company was founded in 2021, after Hodak left Neuralink, where he had been a co-founder and president. Science Corporation initially set out to pursue advanced neural engineering and BCI systems. Its decision to begin with an eye implant reflects a more focused route into a field often associated with far broader claims about links between machines and the nervous system. The latest procedure gives that route a concrete patient milestone, but it remains an early point in the process rather than a completed demonstration of a finished therapy.

Technical limits are already part of the next phase. Hodak said the team wants to expand the system's field of view. Accomplishing that would require addressing the curved shape of the eye as the implant grows, while also shrinking electrodes to move toward finer image detail. Those engineering demands underline why an implantation and a proven treatment are different milestones: the device must not only function safely, but also deliver useful visual information at a scale and resolution that matter in daily life.

The program also illustrates a different way of looking at assistive implants. Cochlear devices, retinal systems and motor prostheses have typically been discussed through the needs they address—hearing, sight or movement. Hodak's description groups them around their relationship with the nervous system instead. Supporters of that approach may see a common technical foundation across these devices. A more cautious reading is that each target organ, condition and patient group presents its own biological and clinical questions, so progress in one setting does not automatically predict results in another.

Science Corporation has signaled that vision will not be its only area of interest. Hodak said the company's first additional clinical indication has not yet been publicly named, though he characterized it as a widely known neurodegenerative condition. He also mentioned stroke as another area under consideration. Neither comment provided a product, schedule or trial plan, leaving the retina program as the company's clearest disclosed clinical step for now.

What comes next will be watched on several levels: evidence of benefit for the implanted patient, the device's safety profile, and whether the planned improvements in viewing area and detail can be delivered. The announcement is notable because it connects a first human implantation in Stargardt disease with a broader BCI strategy. Its ultimate importance, however, will depend on clinical follow-up and on what Science Corporation can show beyond the initial procedure.

Source: TechCrunch